Back to top

Analyst Blog

Alnylam Pharmaceuticals Inc. (ALNY - Analyst Report) recently initiated a phase I study on ALN-TTRsc. ALN-TTRsc is a ribo nucleic acid interference (RNAi) therapeutic that targets transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).

The company is developing the candidate for the treatment of familial amyloidotic cardiomyopathy (FAC). The company is expected to enrol around 40 healthy volunteers for the study. The study will evaluate the safety and tolerability of ALN-TTRsc in these volunteers.

The company expects data from the study in mid-2013. Depending on the results from the phase I study, Alnylam plans to initiate a phase II study on ALN-TTRsc in patients suffering from FAC by the end of this year and a pivotal study for ALN-TTRsc in FAC patients in 2014.

Alnylam is collaborating with Genzyme, a Sanofi (SNY - Analyst Report) company, for the development and commercialization of RNAi therapeutics in Japan and the broader Asian-Pacific region. Alnylam is responsible for the same in North and South America, Europe, and the rest of the world.

Earlier this year, Alnylam had provided a brief update on its key “Alnylam 5x15” pipeline, which aims to develop RNAi therapeutic candidates and partner programs for the next couple of years. The company is expecting several study results and initiations based on its RNAi therapeutic candidates in the next two years.

We believe that the company is progressing well with its “Alnylam 5x15” pipeline. We expect investor focus to stay on the successful development of the pipeline, though most of the candidates are in early stages of development.

Alnylam carries a Zacks Rank #3 (Hold). However, other biopharmaceutical stocks such as Athersys Inc. (ATHX - Snapshot Report) and Array BioPharma Inc. (ARRY - Snapshot Report) currently carry a Zacks Rank #1 (Strong Buy) and Zacks Rank #2 (Buy) respectively.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%